These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24564812)

  • 21. Impact of medicare part D plan features on use of generic drugs.
    Tang Y; Gellad WF; Men A; Donohue JM
    Med Care; 2014 Jun; 52(6):541-8. PubMed ID: 24824538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of the US Medicare Part D coverage gaps on medication use among patients with depression and heart failure.
    Baik SH; Rollman BL; Reynolds CF; Lave JR; Smith KJ; Zhang Y
    J Ment Health Policy Econ; 2012 Sep; 15(3):105-18. PubMed ID: 23001279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
    Sheingold S; Nguyen NX
    Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential impact of pharmacist interventions to reduce cost for Medicare Part D beneficiaries.
    Thatcher EE; Vanwert EM; Erickson SR
    J Pharm Pract; 2013 Jun; 26(3):248-52. PubMed ID: 23178417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
    Fischer MA; Avorn J
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measuring economic impact of applying daily average consumption limits.
    Flavin BM; Nishida LM; Karbowicz SH; Renner ME; Leonard RJ
    J Manag Care Pharm; 2014 Feb; 20(2):159-64. PubMed ID: 24456317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brand-name prescription drug use among Veterans Affairs and Medicare Part D patients with diabetes: a national cohort comparison.
    Gellad WF; Donohue JM; Zhao X; Mor MK; Thorpe CT; Smith J; Good CB; Fine MJ; Morden NE
    Ann Intern Med; 2013 Jul; 159(2):105-14. PubMed ID: 23752663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
    Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
    Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medicare beneficiaries' out-of-pocket costs for commonly used generic drugs, 2009-2017.
    Liu P; Dhruva SS; Shah ND; Ross JS
    Am J Manag Care; 2020 Mar; 26(3):112-117. PubMed ID: 32181626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How do seniors respond to 100% cost-sharing for prescription drugs? Quality of the evidence underlying opinions about the Medicare Part D coverage gap.
    Fairman KA; Curtiss FR
    J Manag Care Pharm; 2011 Jun; 17(5):382-92. PubMed ID: 21657807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sending The Wrong Price Signal: Why Do Some Brand-Name Drugs Cost Medicare Beneficiaries Less Than Generics?
    Dusetzina SB; Jazowski S; Cole A; Nguyen J
    Health Aff (Millwood); 2019 Jul; 38(7):1188-1194. PubMed ID: 31260351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends in Medicare Part D coverage of generics with equivalent brand-name drugs.
    Dusetzina SB; Cubanski J; Roberts AW; Hoadley J; True S; Nshuti L; Neuman T
    Am J Manag Care; 2021 Jul; 27(7):283-288. PubMed ID: 34314117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Web-based survey to assess the perceptions of managed care organization representatives on use of copay subsidy coupons for prescription drugs.
    Nemlekar P; Shepherd M; Lawson K; Rush S
    J Manag Care Pharm; 2013 Oct; 19(8):602-8. PubMed ID: 24074006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medicare Part D: Patients Bear The Cost Of 'Me Too' Brand-Name Drugs.
    Gastala NM; Wingrove P; Gaglioti A; Petterson S; Bazemore A
    Health Aff (Millwood); 2016 Jul; 35(7):1237-40. PubMed ID: 27385239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generic script share and the price of brand-name drugs: the role of consumer choice.
    Rizzo JA; Zeckhauser R
    Int J Health Care Finance Econ; 2009 Sep; 9(3):291-316. PubMed ID: 19130220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends in the prescription drug plans delivering the Medicare Part D prescription drug benefit.
    Brill JV
    Am J Health Syst Pharm; 2007 Aug; 64(15 Suppl 10):S3-6; quiz S21-S23. PubMed ID: 17646551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medicare Part D roulette: potential implications of random assignment and plan restrictions.
    Patel RA; Walberg MP; Woelfel JA; Amaral MM; Varu P
    Medicare Medicaid Res Rev; 2013; 3(2):. PubMed ID: 24753963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Medicare Part D coverage gap closure on utilization of branded and generic drugs.
    Liu J; Zhang Y; Kaplan CM
    Health Econ; 2023 Mar; 32(3):639-653. PubMed ID: 36399360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Digesting the doughnut hole.
    Joyce GF; Zissimopoulos J; Goldman DP
    J Health Econ; 2013 Dec; 32(6):1345-55. PubMed ID: 24308883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying widely covered drugs and drug coverage variation among Medicare part D formularies.
    Tseng CW; Mangione CM; Brook RH; Keeler E; Dudley RA
    JAMA; 2007 Jun; 297(23):2596-602. PubMed ID: 17579228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.